Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Research & Development: 2009-2024

Historic Research & Development for Ironwood Pharmaceuticals (IRWD) over the last 16 years, with Dec 2024 value amounting to $111.4 million.

  • Ironwood Pharmaceuticals' Research & Development fell 24.67% to $22.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $98.7 million, marking a year-over-year decrease of 18.93%. This contributed to the annual value of $111.4 million for FY2024, which is 4.02% down from last year.
  • As of FY2024, Ironwood Pharmaceuticals' Research & Development stood at $111.4 million, which was down 4.02% from $116.1 million recorded in FY2023.
  • In the past 5 years, Ironwood Pharmaceuticals' Research & Development registered a high of $116.1 million during FY2023, and its lowest value of $44.3 million during FY2022.
  • In the last 3 years, Ironwood Pharmaceuticals' Research & Development had a median value of $111.4 million in 2024 and averaged $90.6 million.
  • Per our database at Business Quant, Ironwood Pharmaceuticals' Research & Development crashed by 37.13% in 2022 and then surged by 162.25% in 2023.
  • Yearly analysis of 5 years shows Ironwood Pharmaceuticals' Research & Development stood at $88.1 million in 2020, then dropped by 20.05% to $70.4 million in 2021, then plummeted by 37.13% to $44.3 million in 2022, then soared by 162.25% to $116.1 million in 2023, then decreased by 4.02% to $111.4 million in 2024.